Background
Mohs Micrographic Surgery (MMS) with melanoma antigen recognized by T
cells (MART-1) immunostaining is an effective treatment for cutaneous
melanoma.
Objective
Determine the efficacy of MMS with MART-1 immunostains in the
management of invasive and in-situ melanoma.
Methods and Materials
A retrospective cohort study evaluated 2, 114 melanomas in 1,982
patients excised using MMS and MART-1 immunostains. Margins required for
excision were calculated based on Breslow thickness, location and size.
Survival and local recurrence rates were calculated and compared with those
of historical controls.
Results
The mean follow-up was 3.73 years. Local recurrence was identified in
0.49 % (7/1,419) of primary melanomas. ~82% of melanomas
were excised with ≤6mm margins. The surgical margin was
significantly related to tumor location and size, but not to Breslow
thickness. The five-year Kaplan-Meier local recurrence and disease-specific
survival were 0.59 ± 0.30 and 98.53 ± 0.42, respectively.
MMS with MART-1 immunostains achieved lower local recurrence rates, and
equivalent or higher Kaplan-Meier survival rates when compared with
conventional wide local excision.
Conclusion
MMS with MART-1 immunostain is an effective treatment for melanoma as
evidenced by low local recurrence rates. It offers the advantage of more
tissue conserving margins than those recommended for conventional
excision.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.